Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Unlike other breast cancer subtypes, patients with triple negative breast cancer (TNBC) have poor outcomes and no effective targeted therapies, leaving an unmet need for therapeutic targets. Efforts to profile these tumors have revealed the PI3K/AKT/mTOR pathway as a potential target. Activation of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cells
Main Authors: Wen, Wei, Marcinkowski, Emily, Luyimbazi, David, Luu, Thehang, Xing, Quanhua, Yan, Jin, Wang, Yujun, Wu, Jun, Guo, Yuming, Tully, Dylan, Han, Ernest S., Yost, Susan E., Yuan, Yuan, Yim, John H.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770784/
https://ncbi.nlm.nih.gov/pubmed/31480338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells8091010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados